Innovative Trivalent Nanobody Targeting ALB and CALCRL for Migraine Therapy

VHH-P345 is a humanized nanobody-based therapeutic candidate currently in the Biological Testing stage, engineered to target both albumin (ALB) and calcitonin receptor like receptor (CALCRL). This novel molecule is designed for the treatment of migraine, leveraging the dual targeting capability to modulate key pathways implicated in the condition. By focusing on the extracellular domains of ALB and CALCRL, VHH-P345 offers a strategically differentiated approach to migraine intervention and highlights the promise of multi-targeted nanobody therapies in neurological disorders.

Licensing Opportunity

VHH-P345 is available for out-licensing to strategic partners interested in advancing novel therapies for migraine. We welcome inquiries from collaborators seeking to co-develop or commercialize this differentiated nanobody asset.

Development Phase

Modality

VHH-P345 features a trivalent architecture comprising three single-domain antibodies arranged in tandem and joined by flexible linkers, all expressed in human embryonic kidney cells. This nanobody construct is designed to bind two distinct extracellular epitopes on CALCRL and one on ALB, enhancing both specificity and therapeutic impact. The compact size and unique single-domain nature of nanobodies confer improved tissue penetration and stability, making VHH-P345 particularly advantageous for conditions such as migraine where deep tissue access and prolonged circulation may overcome limitations of conventional antibodies. This innovative modality supports versatile development paths, including advanced formulation and delivery.

Target

ALB and CALCRL serve as dual targets for VHH-P345. ALB, a major plasma protein, regulates drug distribution and half-life by binding and transporting diverse molecules, and is widely expressed in the circulatory system. CALCRL, a G protein-coupled receptor, is chiefly found in neural and vascular tissues, where it regulates neurogenic inflammation and vascular tone. Dysregulation of CALCRL is linked to migraine pathogenesis, as it mediates signaling involved in pain transmission and vasodilation. Targeting both ALB and CALCRL allows VHH-P345 to maximize therapeutic half-life via ALB engagement and modulate migraine-relevant pathways through CALCRL antagonism, representing a strategic asset in neurovascular drug development.

Mechanism of Action

VHH-P345 exerts its therapeutic effect in migraine by simultaneously binding to extracellular regions of CALCRL and ALB. The anti-CALCRL activity blocks receptor function, interfering with calcitonin gene-related peptide mediated signaling, known to contribute to neuronal sensitization and vasodilation in migraine attacks. Simultaneous engagement with ALB enables VHH-P345 to leverage albumin’s extended half-life and systemic distribution, optimizing pharmacokinetics. As a signal transduction modulator, this trivalent nanobody can be further adapted for advanced applications such as antibody-drug conjugates or multispecific formats, underscoring its potential as a flexible nanobody platform in neurology and beyond.

Migraine

Migraine is a prevalent and disabling neurological disorder characterized by recurrent headaches, often accompanied by nausea, photophobia, and phonophobia. Neurological and vascular mechanisms contribute to migraine pathophysiology, with neuropeptides such as CGRP and its receptor CALCRL playing crucial roles in pain transmission and inflammation. Epidemiological studies have identified migraine as a leading cause of disability worldwide, particularly in working-age adults and women. Current treatments encompass analgesics, preventative medications, and biologic agents targeting neuropeptide pathways. However, many patients experience limited efficacy, intolerable side effects, or inadequate response with existing therapies. The therapeutic potential of VHH-P345 lies in its dual-targeting approach—addressing both prolonged systemic exposure via ALB and robust pathway modulation via CALCRL blockade—offering an innovative option that may address currently unmet needs in migraine care.